Understand the source comparison
IGF-1 LR3 vs Native IGF-1: Mechanism Comparison
Half-Life 20–30 hours 10–15 minutes IGF-1 LR3's extended half-life allows once-daily dosing and sustained receptor occupancy throughout recovery windows. Native IGF-1 requires multiple daily doses and still produces inconsistent serum levels Binding Protein Af
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Half-Life
- 20–30 hours
- 10–15 minutes
- IGF-1 LR3's extended half-life allows once-daily dosing and sustained receptor occupancy throughout recovery windows. Native IGF-1 requires multiple daily doses and still produces inconsistent serum levels
- Binding Protein Affinity
- Reduced by 90% (avoids IGFBP sequestration)
- High (70–90% bound at any time)
- LR3's poor IGFBP binding keeps more peptide in free circulation, increasing tissue bioavailability 3–5× compared to native IGF-1 despite identical receptor affinity
- Receptor Selectivity
- IGF-1R preferential
- IGF-1R and insulin receptor cross-reactivity
- LR3 shows minimal insulin receptor activation at research doses, reducing hypoglycemia risk. Native IGF-1 at equivalent anabolic doses frequently causes blood glucose instability
- Stability in Solution
- Moderate (28-day refrigerated shelf life)
- Poor (degrades within 8–12 hours post-reconstitution)
- LR3's structural modifications improve solution stability significantly, making it practical for multi-week protocols. Native IGF-1 requires daily reconstitution or lyophilisation with specialized stabilizers
- Satellite Cell Activation
- Potent (3–5× baseline proliferation in vitro)
- Moderate (1.5–2× baseline)
- Both activate satellite cells through mTOR and MAPK pathways, but LR3's prolonged receptor occupancy produces cumulative signaling that native IGF-1's short half-life cannot match